SUNNYVALE, Calif.--(BUSINESS WIRE)--Paracor Medical, Inc. announced today the initiation of enrollment in the Company-sponsored pivotal clinical trial of its HeartNet(TM) therapy, designated PEERLESS-HF (Prospective Evaluation of Elastic Restraint to LESSen the effects of Heart Failure). The HeartNet implant, an elastic structure delivered in a minimally invasive thoracotomy procedure in about one hour, provides support to the walls of the heart’s pumping chambers, the ventricles. This elastic support is intended to augment the function of the heart, and to potentially attenuate or reverse the negative remodeling associated with the advanced stages of heart failure.
